164 related articles for article (PubMed ID: 37849799)
1. The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling.
Li S; Chen D; Guo H; Liu D; Yang C; Zhang R; Wang T; Zhang F; Bai X; Yang Y; Sun N; Zhang W; Zhang L; Zhao G; Peng L; Tu X; Tian W
Front Oncol; 2023; 13():1240061. PubMed ID: 37849799
[TBL] [Abstract][Full Text] [Related]
2. ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade.
Silence K; Dreier T; Moshir M; Ulrichts P; Gabriels SM; Saunders M; Wajant H; Brouckaert P; Huyghe L; Van Hauwermeiren T; Thibault A; De Haard HJ
MAbs; 2014; 6(2):523-32. PubMed ID: 24492296
[TBL] [Abstract][Full Text] [Related]
3. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
[TBL] [Abstract][Full Text] [Related]
4. SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal.
Yu J; Li S; Chen D; Liu D; Guo H; Yang C; Zhang W; Zhang L; Zhao G; Tu X; Peng L; Liu S; Bai X; Song Y; Jiang Z; Zhang R; Tian W
J Hematol Oncol; 2022 Nov; 15(1):167. PubMed ID: 36384978
[TBL] [Abstract][Full Text] [Related]
5. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.
McEarchern JA; Oflazoglu E; Francisco L; McDonagh CF; Gordon KA; Stone I; Klussman K; Turcott E; van Rooijen N; Carter P; Grewal IS; Wahl AF; Law CL
Blood; 2007 Feb; 109(3):1185-92. PubMed ID: 17038522
[TBL] [Abstract][Full Text] [Related]
6. Fcγ receptor binding is required for maximal immunostimulation by CD70-Fc.
Dadas O; Allen JD; Buchan SL; Kim J; Chan HTC; Mockridge CI; Duriez PJ; Rogel A; Crispin M; Al-Shamkhani A
Front Immunol; 2023; 14():1252274. PubMed ID: 37965342
[TBL] [Abstract][Full Text] [Related]
7. Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy.
Guelen L; Fischmann TO; Wong J; Mauze S; Guadagnoli M; Bąbała N; Wagenaars J; Juan V; Rosen D; Prosise W; Habraken M; Lodewijks I; Gu D; Stammen-Vogelzangs J; Yu Y; Baker J; Lutje Hulsik D; Driessen-Engels L; Malashock D; Kreijtz J; Bertens A; de Vries E; Bovens A; Bramer A; Zhang Y; Wnek R; Troth S; Chartash E; Dobrenkov K; Sadekova S; van Elsas A; Cheung JK; Fayadat-Dilman L; Borst J; Beebe AM; Van Eenennaam H
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100308
[TBL] [Abstract][Full Text] [Related]
8. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
Tai YT; Horton HM; Kong SY; Pong E; Chen H; Cemerski S; Bernett MJ; Nguyen DH; Karki S; Chu SY; Lazar GA; Munshi NC; Desjarlais JR; Anderson KC; Muchhal US
Blood; 2012 Mar; 119(9):2074-82. PubMed ID: 22246035
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.
Wang QJ; Yu Z; Hanada KI; Patel K; Kleiner D; Restifo NP; Yang JC
Clin Cancer Res; 2017 May; 23(9):2267-2276. PubMed ID: 27803044
[No Abstract] [Full Text] [Related]
10. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
11. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.
Riether C; Pabst T; Höpner S; Bacher U; Hinterbrandner M; Banz Y; Müller R; Manz MG; Gharib WH; Francisco D; Bruggmann R; van Rompaey L; Moshir M; Delahaye T; Gandini D; Erzeel E; Hultberg A; Fung S; de Haard H; Leupin N; Ochsenbein AF
Nat Med; 2020 Sep; 26(9):1459-1467. PubMed ID: 32601337
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.
Wingert S; Reusch U; Knackmuss S; Kluge M; Damrat M; Pahl J; Schniegler-Mattox U; Mueller T; Fucek I; Ellwanger K; Tesar M; Haneke T; Koch J; Treder M; Fischer W; Rajkovic E
MAbs; 2021; 13(1):1950264. PubMed ID: 34325617
[TBL] [Abstract][Full Text] [Related]
13. Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma.
Benhamouda N; Sam I; Epaillard N; Gey A; Phan L; Pham HP; Gruel N; Saldmann A; Pineau J; Hasan M; Quiniou V; Nevoret C; Verkarre V; Libri V; Mella S; Granier C; Broudin C; Ravel P; De Guillebon E; Mauge L; Helley D; Jabla B; Chaput N; Albiges L; Katsahian S; Adam J; Mejean A; Adotevi O; Vano YA; Oudard S; Tartour E
Clin Cancer Res; 2022 Nov; 28(22):4983-4994. PubMed ID: 36067339
[TBL] [Abstract][Full Text] [Related]
14. CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
Al Sayed MF; Ruckstuhl CA; Hilmenyuk T; Claus C; Bourquin JP; Bornhauser BC; Radpour R; Riether C; Ochsenbein AF
Blood; 2017 Jul; 130(3):297-309. PubMed ID: 28495792
[TBL] [Abstract][Full Text] [Related]
15. Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Leupin N; Zinzani PL; Morschhauser F; Dalle S; Maerevoet M; Michot JM; Ribrag V; Offner F; Beylot-Barry M; Moins-Teisserenc H; Zwaenepoel K; de Winne K; Battistella M; Hultberg A; Gandini D; Moshir M; Jacobs J; Delahaye T; Khan A; Zabrocki P; Silence K; van Rompaey L; Borg C; Motta G; Melle F; Calleri A; Pauwels P; de Haard H; Pileri S; Bagot M
Cancer; 2022 Mar; 128(5):1004-1014. PubMed ID: 34726773
[TBL] [Abstract][Full Text] [Related]
16. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
[TBL] [Abstract][Full Text] [Related]
17. An open-label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma.
De Meulenaere A; Vermassen T; Creytens D; De Keukeleire S; Delahaye T; Deron P; Duprez F; Fung S; Pauwels P; Ferdinande L; Rottey S
Clin Transl Sci; 2021 Nov; 14(6):2300-2313. PubMed ID: 34405542
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27.
Yoshino K; Kishibe K; Nagato T; Ueda S; Komabayashi Y; Takahara M; Harabuchi Y
Br J Haematol; 2013 Feb; 160(3):331-42. PubMed ID: 23206232
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of CD70 and CD27.
Wajant H
Expert Opin Ther Targets; 2016 Aug; 20(8):959-73. PubMed ID: 26914723
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of prognosis and immune function of CD70-CD27 signaling axis in pan-cancer.
Kong F; Ye Q; Xiong Y
Funct Integr Genomics; 2023 Jan; 23(1):48. PubMed ID: 36700974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]